Program
Telmisartan
Also written as “telmisartan”, “CKD-828, D097, D337” and “Telmisartan 40 mg”.
Its studies are mostly in Hypertension · Essential Hypertension · Diabetic Nephropathies · Hypercholesterolemia · Hyperlipidemias, led by 15 companies.
Drug pageTelmisartan: every studyMany companies study it; this page follows only the 130 they lead. All 177 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Boehringer Ingelheimits history only | 900 open or running | phase 4since May 2, 2002 | May 2, 2002 | none ahead |
| Chong Kun Dang Pharmaceutical | 122 open or running | phase 4since Mar 9, 2023 | May 20, 2010 | none ahead |
| Yuhanits history only | 81 open or running | phase 4since Nov 10, 2016 | May 29, 2014 | none ahead |
| IlDong Pharmaceuticalits history only | 40 open or running | phase 3since Mar 5, 2014 | Mar 5, 2014 | none ahead |
| Jeil Pharmaceuticalits history only | 30 open or running | phase 3since Mar 8, 2017 | Mar 9, 2015 | none ahead |
| Daewon Pharmaceuticalits history only | 20 open or running | phase 3since Oct 12, 2016 | Oct 12, 2016 | none ahead |
| George Medicines PTYits history only | 20 open or running | phase 3since Aug 15, 2020 | Aug 15, 2020 | none ahead |
| HK inno.Nits history only | 20 open or running | phase 1since Aug 25, 2021 | Aug 25, 2021 | none ahead |
| Daewoong Pharmaceuticalits history only | 10 open or running | phase 1since Mar 4, 2013 | Mar 4, 2013 | none ahead |
| DongKoo Bio & Pharmaits history only | 10 open or running | phase 1since Feb 8, 2018 | Feb 8, 2018 | none ahead |
| Hanlim Pharm.its history only | 10 open or running | phase 3since Dec 2, 2020 | Dec 2, 2020 | none ahead |
| Huons Globalits history only | 11 open or running | phase 1since Aug 5, 2026 | Aug 5, 2026 | Apr 2027phase 1 · NCT07784608 |
| Pharmtechnologyits history only | 10 open or running | phase 1since Oct 8, 2018 | Oct 8, 2018 | none ahead |
| Samil Pharmaceuticalits history only | 10 open or running | phase 1since Oct 13, 2015 | Oct 13, 2015 | none ahead |
| THPharmits history only | 10 open or running | phase 1since Sep 8, 2023 | Sep 8, 2023 | none ahead |
Also a collaborator on its studies: Linical Korea, GlaxoSmithKline and Bayer.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Chong Kun Dang Pharmaceutical only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 20, 2010First study: phase 2 study in HypertensionFirst studyNCT01128322 · 430 enrolled · Korea, Republic of
- May 17, 2011Phase 1 study in Healthy Male VolunteersNCT01356017 · 32 enrolled · Korea, Republic of
- Apr 25, 2013Phase 1 study in Essential HypertensionNCT01842230 · 24 enrolled · Korea, Republic of
- Jan 24, 2014Phase 1 study in HypertensionNCT02047175 · 64 enrolled · Korea, Republic of
- Feb 5, 2020Phase 1 study in HypertensionNCT04258865 · 30 enrolled · Korea, Republic of
- Apr 29, 2021Phase 1 study in HypertensionNCT04883658 · 62 enrolled · Korea, Republic of
- Jan 4, 2022Phase 1 study in HypertensionNCT05192356 · 63 enrolled · Korea, Republic of
- Sep 18, 2022Phase 1 study in HypertensionNCT05549401 · 32 enrolled · Korea, Republic of
- Feb 20, 2023Phase 1 study in HypertensionNCT05749861 · 65 enrolled · Korea, Republic of
- Mar 9, 2023Phase 4 study in Essential HypertensionNCT05843162 · 116 planned
- Oct 29, 2023Phase 1 study in HypertensionNCT06112678 · 63 enrolled · Korea, Republic of
- May 22, 2024Phase 4 study in Diabetic NephropathiesNCT06431477 · 98 planned · Korea, Republic of
TargetBeta
“Type-1 angiotensin II receptor antagonist”ChEMBL 37, by rule
Other programs on AGTR1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Valsartanrule | Novartis | phase 4 | 145 |
| Losartanrule | Organon | phase 4 | 58 |
| azilsartan medoxomilrule | Takeda | phase 4 | 25 |
| sparsentanrule | travere-therapeutics-inc | phase 4 | 9 |
Studies
All 12 Chong Kun Dang Pharmaceutical leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06431477Diabetic Nephropathies · Korea, Republic of | 4 | Recruiting | Oct 31, 2025 | 98 |
| NCT06112678Hypertension · Korea, Republic of | 1 | Completed | Feb 19, 2024 | 63 |
| NCT05843162Essential Hypertension | 4 | Not yet recruiting | Dec 31, 2023 | 116 |
| NCT05749861Hypertension · Korea, Republic of | 1 | Completed | Jun 7, 2023 | 65 |
| NCT05549401Hypertension · Korea, Republic of | 1 | Completed | Nov 30, 2022 | 32 |
| NCT05192356Hypertension · Korea, Republic of | 1 | Completed | May 8, 2022 | 63 |
| NCT04883658Hypertension · Korea, Republic of | 1 | Completed | Jul 20, 2021 | 62 |
| NCT04258865Hypertension · Korea, Republic of | 1 | Completed | Apr 26, 2020 | 30 |
| NCT02047175Hypertension · Korea, Republic of | 1 | Completed | Mar 2014 | 64 |
| NCT01842230Essential Hypertension · Korea, Republic of | 1 | Completed | May 2013 | 24 |
| NCT01356017Healthy Male Volunteers · Korea, Republic of | 1 | Completed | Sep 2011 | 32 |
| NCT01128322Hypertension · Korea, Republic of | 2 | Completed | Mar 2011 | 430 |
How it is read
Names in the registry
- “Telmisartan”, 38 entries
- “telmisartan”, 7 entries
- “CKD-828, D097, D337”, 6 entries
- “Telmisartan 40 mg”, 6 entries
- “Low dose of telmisartan”, 4 entries
Conditions, from the studies’ own filings
- Hypertension, 77 studies
- Essential Hypertension, 6 studies
- Diabetic Nephropathies, 3 studies
- Hypercholesterolemia, 2 studies
- Hyperlipidemias, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.